School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK.
Syst Rev. 2021 Nov 1;10(1):290. doi: 10.1186/s13643-021-01842-y.
Subclinical hypothyroidism is a thyroid disorder diagnosed from the laboratory blood test results of otherwise asymptomatic patients. It has been associated with poor cardiovascular outcomes, mortality and progression to overt thyroid hormone deficiency. Current guidelines on the management of subclinical hypothyroidism differ because of conflicting evidence on long-term treatment benefits. Even though there are several existing systematic reviews on its clinical outcomes, no definitive conclusion has been reached yet. As such, a new synthesis could help provide more insight and consensus on this topic. To this purpose, this umbrella review will evaluate and synthesise current evidence on the long-term clinical outcomes of the different management strategies for subclinical hypothyroidism.
This is a protocol for an umbrella review on the management strategies for subclinical hypothyroidism. We will conduct literature searches in multiple electronic databases (from inception onwards), namely MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, JBI Evidence Synthesis, Epistemonikos database, PDQ Evidence and the PROSPERO register. There will be no restriction on the date or language of publication. Additional material will be identified through grey literature searches and citation chaining. Review inclusion criteria will be patients with subclinical hypothyroidism, receiving treatment or monitoring, no restrictions on the comparators used and with cardiovascular events, frailty fractures, quality of life and all-cause mortality as primary outcomes of interest. Two reviewers will independently screen all citations, full-text articles and abstract data on a pre-piloted form in duplicate. Methodological quality (or bias) of included studies will be appraised using AMSTAR-2. Any conflicts that arise will be resolved through discussion or involving a third reviewer. A narrative synthesis will be provided with information presented in the main text and tables to summarise and explain the characteristics and findings of the included reviews. Even so, it is not expected that a meta-analysis will be performed due to review variability. Study limitations and methodological quality assessments will also be reported to provide context for the overall summary of evidence.
This review will provide a comprehensive summary of the effects of the pharmacological and non-pharmacological management of subclinical hypothyroidism on specific long-term clinical outcomes. It is anticipated that the findings of this umbrella review will aid in the development of consensus-based clinical recommendations for subclinical hypothyroidism, as well as highlight areas for future research. Review findings will be disseminated primarily through peer-reviewed publications.
PROSPERO CRD42021235172.
亚临床甲状腺功能减退症是一种通过对无症状患者的实验室血液检测结果诊断的甲状腺疾病。它与不良心血管结局、死亡率和向明显甲状腺激素缺乏的进展有关。目前的亚临床甲状腺功能减退症管理指南存在差异,因为长期治疗益处的证据相互矛盾。尽管已经有几项关于其临床结果的系统评价,但尚未得出明确的结论。因此,新的综合分析可能有助于就该主题提供更多的见解和共识。为此,本综述伞评估并综合当前关于亚临床甲状腺功能减退症不同管理策略的长期临床结果的证据。
这是一篇关于亚临床甲状腺功能减退症管理策略的综述伞的方案。我们将在多个电子数据库(从成立开始)中进行文献检索,即 MEDLINE、EMBASE、Scopus、Web of Science、Cochrane 系统评价数据库、JBI 证据综合、Epistemonikos 数据库、PDQ 证据和 PROSPERO 登记处。出版物的日期或语言没有限制。通过灰色文献检索和引文链接将确定额外的材料。综述纳入标准为接受治疗或监测的亚临床甲状腺功能减退症患者,对使用的对照物没有限制,以心血管事件、脆弱性骨折、生活质量和全因死亡率为主要关注的结局。两名审查员将独立地在预试验表格上重复筛选所有引用、全文文章和摘要数据。使用 AMSTAR-2 评估纳入研究的方法学质量(或偏倚)。出现的任何争议将通过讨论或涉及第三名审查员来解决。将提供叙述性综合,以文本和表格中的信息总结和解释纳入综述的特征和发现。即便如此,由于综述的变异性,预计不会进行荟萃分析。还将报告研究局限性和方法学质量评估,为整体证据总结提供背景。
本综述将全面总结亚临床甲状腺功能减退症的药理学和非药理学管理对特定长期临床结局的影响。预计本综述伞的结果将有助于制定基于共识的亚临床甲状腺功能减退症临床建议,并突出未来研究的领域。审查结果将主要通过同行评议出版物传播。
PROSPERO CRD42021235172。